← Leaderboards
Edward P Amento
Theracos, Inc.
$931,250
Attributed
$931,250
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $292.5K · FY2005–23$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$931,250 · 4
By mechanism
R21$536,250 · 1
R43$200,000 · 2
R03$195,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “In Vitro”
- David Heimbrook · Leidos Biomedical Research, Inc.$553,787,942
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Dennis R. Burton · Scripps Research Institute$79,204,175
Research focus
In VitroIn VivoProductionPathway InteractionsReceptor ActivationAdenosineDesignCytokineInflammatoryMediatingRadiolabeledReceptorSiteTissuesAffinityCellsAgonistCyclic AmpHomeostasisInflammationAnti-Inflammatory AgentsAnti-InflammatoryAntibodiesAdverse Event
Grant awards (6)
Function- and interaction-based discovery of negative allosteric modulators of the A2A Receptor$97,500
R03 · FY2023 · AI · contact PI
Function- and interaction-based discovery of negative allosteric modulators of the A2A Receptor$97,500
R03 · FY2022 · AI · contact PI
Positive allosteric modulation of the A2aR for treatment of acute inflammation$243,750
R21 · FY2015 · AI · contact PI
Positive allosteric modulation of the A2aR for treatment of acute inflammation$292,500
R21 · FY2014 · AI · contact PI
THR-0921 for Cardiovascular Complications of Diabetes$100,000
R43 · FY2006 · DK · contact PI
Novel PPAR alpha/gamma Agonist for Type 2 Diabetes$100,000
R43 · FY2005 · DK